Structural Optimization of 2-(2-aminopyridin-4-yl)-n-(3-carbamoyl-1h-pyrazol-4-yl)-1,3-oxazole-4-carboxamide Derivatives As Potent Interleukin-1 Receptor-Associated Kinase 4 Inhibitors